The company, which is developing an ultrasound-based platform for the treatment of bladder diseases and problems, will use the fundraising to complete the pre-clinical phase.31
Vensica Medical, a portfolio company of the Trendlines Group, announces the completion of a fundraising round of $500,000 through private investors. The capital raised will allow the company, which is developing an ultrasound-based platform to treat bladder diseases and problems, to finish the pre-clinical phase.
Vensica Medica, a portfolio company of the technology incubator Trendlines Medical, has developed an innovative ultrasound-based platform, intended for the treatment of bladder diseases and problems. The unique system developed by the company, known as VensiCare, consists of a catheter and ultrasound transducers that increase the permeability of the bladder mucosa, and enable more efficient absorption and a high concentration of drugs, in a simple and quick ambulatory procedure, without anesthesia, needles or pain.
The capital raised will allow the company to complete preclinical trials and prepare for the first human trial which is scheduled to begin in the middle of next year.
The unique technology developed by the company changes the rules of the game in the treatment of a variety of bladder problems, such as irritable bladder syndrome. Over 39 million people in the US alone suffer from irritable bladder syndrome, which manifests itself in a frequent need to urinate. The syndrome is especially common among menopausal and perimenopause women, and causes considerable damage to their quality of life. Over the years, a number of drugs have been developed that cause side effects, and there is also a complicated, expensive and painful procedure that is carried out in an operating room. Through the VensiCare system, on the other hand, the patients will receive an effective therapeutic response, without the need for anesthesia and without pain.
The urology medical devices market is estimated at approximately 5 billion dollars per year with an annual growth of 6%, with the main players in the arena being large international companies. The innovative development of the Vensica Medical company responds to the market demands for a safe solution that does not cause damage to the bladder tissue, is not painful and without changing the accepted treatment procedure for the disease.
Avner Geva, founder and CEO of Vensica Medical: "Vensica Medical is grateful for the trust placed in us by the investors, and looks forward to the completion of the product and entry into human trials with the help of the investment."
